nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—EBP—Raloxifene—osteoporosis	0.326	0.48	CbGbCtD
Trifluoperazine—SIGMAR1—Raloxifene—osteoporosis	0.14	0.206	CbGbCtD
Trifluoperazine—HTR6—Raloxifene—osteoporosis	0.105	0.155	CbGbCtD
Trifluoperazine—CYP1A2—Estropipate—osteoporosis	0.0332	0.049	CbGbCtD
Trifluoperazine—ABCB1—Ethinyl Estradiol—osteoporosis	0.0187	0.0276	CbGbCtD
Trifluoperazine—CYP1A2—Conjugated Estrogens—osteoporosis	0.0157	0.0232	CbGbCtD
Trifluoperazine—CYP1A2—Estradiol—osteoporosis	0.0138	0.0204	CbGbCtD
Trifluoperazine—ABCB1—Conjugated Estrogens—osteoporosis	0.0137	0.0203	CbGbCtD
Trifluoperazine—ABCB1—Estradiol—osteoporosis	0.0121	0.0178	CbGbCtD
Trifluoperazine—S100A4—Calcipotriol—Ergocalciferol—osteoporosis	0.00204	0.334	CbGdCrCtD
Trifluoperazine—S100A4—Calcipotriol—Calcitriol—osteoporosis	0.00204	0.334	CbGdCrCtD
Trifluoperazine—S100A4—Calcipotriol—Cholecalciferol—osteoporosis	0.00174	0.284	CbGdCrCtD
Trifluoperazine—Muscle spasms—Raloxifene—osteoporosis	0.000512	0.00342	CcSEcCtD
Trifluoperazine—Muscle spasms—Ibandronate—osteoporosis	0.000507	0.00338	CcSEcCtD
Trifluoperazine—Angioedema—Estropipate—osteoporosis	0.000502	0.00335	CcSEcCtD
Trifluoperazine—Asthenia—Ergocalciferol—osteoporosis	0.000501	0.00334	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Estradiol—osteoporosis	0.000499	0.00333	CcSEcCtD
Trifluoperazine—Angioedema—Alendronate—osteoporosis	0.000495	0.0033	CcSEcCtD
Trifluoperazine—Agranulocytosis—Pamidronate—osteoporosis	0.000493	0.00329	CcSEcCtD
Trifluoperazine—Weight increased—Zoledronate—osteoporosis	0.000493	0.00329	CcSEcCtD
Trifluoperazine—Oedema peripheral—Risedronate—osteoporosis	0.000492	0.00328	CcSEcCtD
Trifluoperazine—Angioedema—Ibandronate—osteoporosis	0.000482	0.00321	CcSEcCtD
Trifluoperazine—Cough—Estropipate—osteoporosis	0.00048	0.0032	CcSEcCtD
Trifluoperazine—Weight increased—Conjugated Estrogens—osteoporosis	0.000474	0.00317	CcSEcCtD
Trifluoperazine—Agitation—Calcitriol—osteoporosis	0.000474	0.00316	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Conjugated Estrogens—osteoporosis	0.00047	0.00314	CcSEcCtD
Trifluoperazine—Nausea—Calcium Acetate—osteoporosis	0.000469	0.00313	CcSEcCtD
Trifluoperazine—Cough—Raloxifene—osteoporosis	0.000465	0.0031	CcSEcCtD
Trifluoperazine—Agranulocytosis—Zoledronate—osteoporosis	0.00045	0.00301	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Estropipate—osteoporosis	0.000449	0.00299	CcSEcCtD
Trifluoperazine—Convulsion—Calcitriol—osteoporosis	0.000447	0.00298	CcSEcCtD
Trifluoperazine—Constipation—Etidronic acid—osteoporosis	0.000443	0.00296	CcSEcCtD
Trifluoperazine—Dry mouth—Ibandronate—osteoporosis	0.000439	0.00293	CcSEcCtD
Trifluoperazine—Skin disorder—Estropipate—osteoporosis	0.000436	0.00291	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Ibandronate—osteoporosis	0.00043	0.00287	CcSEcCtD
Trifluoperazine—Dry mouth—Calcitriol—osteoporosis	0.00043	0.00287	CcSEcCtD
Trifluoperazine—Muscle spasms—Ethinyl Estradiol—osteoporosis	0.000428	0.00286	CcSEcCtD
Trifluoperazine—Oedema peripheral—Zoledronate—osteoporosis	0.000427	0.00285	CcSEcCtD
Trifluoperazine—Skin disorder—Raloxifene—osteoporosis	0.000422	0.00282	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Calcitriol—osteoporosis	0.000421	0.00281	CcSEcCtD
Trifluoperazine—Skin disorder—Ibandronate—osteoporosis	0.000418	0.00279	CcSEcCtD
Trifluoperazine—Muscle spasms—Risedronate—osteoporosis	0.000418	0.00279	CcSEcCtD
Trifluoperazine—Asthma—Estradiol—osteoporosis	0.000417	0.00278	CcSEcCtD
Trifluoperazine—Dysphagia—Estradiol—osteoporosis	0.000417	0.00278	CcSEcCtD
Trifluoperazine—Nausea—Ergocalciferol—osteoporosis	0.000414	0.00277	CcSEcCtD
Trifluoperazine—Erythema—Pamidronate—osteoporosis	0.000413	0.00276	CcSEcCtD
Trifluoperazine—Urticaria—Etidronic acid—osteoporosis	0.000412	0.00275	CcSEcCtD
Trifluoperazine—Oedema peripheral—Conjugated Estrogens—osteoporosis	0.000411	0.00274	CcSEcCtD
Trifluoperazine—Bronchospasm—Estradiol—osteoporosis	0.00041	0.00274	CcSEcCtD
Trifluoperazine—Skin disorder—Calcitriol—osteoporosis	0.000409	0.00273	CcSEcCtD
Trifluoperazine—Angioedema—Ethinyl Estradiol—osteoporosis	0.000407	0.00272	CcSEcCtD
Trifluoperazine—Insomnia—Estropipate—osteoporosis	0.000406	0.00271	CcSEcCtD
Trifluoperazine—Anorexia—Calcitriol—osteoporosis	0.000401	0.00268	CcSEcCtD
Trifluoperazine—Nervousness—Pamidronate—osteoporosis	0.000401	0.00268	CcSEcCtD
Trifluoperazine—Somnolence—Estropipate—osteoporosis	0.000399	0.00266	CcSEcCtD
Trifluoperazine—Muscle spasms—Pamidronate—osteoporosis	0.000397	0.00265	CcSEcCtD
Trifluoperazine—Angioedema—Risedronate—osteoporosis	0.000397	0.00265	CcSEcCtD
Trifluoperazine—Insomnia—Raloxifene—osteoporosis	0.000393	0.00262	CcSEcCtD
Trifluoperazine—Insomnia—Ibandronate—osteoporosis	0.000389	0.0026	CcSEcCtD
Trifluoperazine—Cough—Ethinyl Estradiol—osteoporosis	0.000389	0.00259	CcSEcCtD
Trifluoperazine—Fatigue—Estropipate—osteoporosis	0.000387	0.00258	CcSEcCtD
Trifluoperazine—Constipation—Estropipate—osteoporosis	0.000384	0.00256	CcSEcCtD
Trifluoperazine—Hypersensitivity—Etidronic acid—osteoporosis	0.000382	0.00255	CcSEcCtD
Trifluoperazine—Insomnia—Calcitriol—osteoporosis	0.000381	0.00254	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Estradiol—osteoporosis	0.000381	0.00254	CcSEcCtD
Trifluoperazine—Weight increased—Estradiol—osteoporosis	0.00038	0.00253	CcSEcCtD
Trifluoperazine—Agitation—Pamidronate—osteoporosis	0.00038	0.00253	CcSEcCtD
Trifluoperazine—Cough—Risedronate—osteoporosis	0.000379	0.00253	CcSEcCtD
Trifluoperazine—Constipation—Alendronate—osteoporosis	0.000378	0.00252	CcSEcCtD
Trifluoperazine—Angioedema—Pamidronate—osteoporosis	0.000377	0.00252	CcSEcCtD
Trifluoperazine—Erythema—Zoledronate—osteoporosis	0.000377	0.00252	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Estradiol—osteoporosis	0.000376	0.00251	CcSEcCtD
Trifluoperazine—Somnolence—Calcitriol—osteoporosis	0.000374	0.0025	CcSEcCtD
Trifluoperazine—Decreased appetite—Ibandronate—osteoporosis	0.000374	0.0025	CcSEcCtD
Trifluoperazine—Fatigue—Ibandronate—osteoporosis	0.000371	0.00247	CcSEcCtD
Trifluoperazine—Leukopenia—Pamidronate—osteoporosis	0.00037	0.00247	CcSEcCtD
Trifluoperazine—Constipation—Ibandronate—osteoporosis	0.000368	0.00245	CcSEcCtD
Trifluoperazine—Pruritus—Etidronic acid—osteoporosis	0.000367	0.00245	CcSEcCtD
Trifluoperazine—Decreased appetite—Calcitriol—osteoporosis	0.000366	0.00244	CcSEcCtD
Trifluoperazine—Erythema—Conjugated Estrogens—osteoporosis	0.000363	0.00242	CcSEcCtD
Trifluoperazine—Muscle spasms—Zoledronate—osteoporosis	0.000363	0.00242	CcSEcCtD
Trifluoperazine—Jaundice—Estradiol—osteoporosis	0.000363	0.00242	CcSEcCtD
Trifluoperazine—Dry mouth—Risedronate—osteoporosis	0.000362	0.00241	CcSEcCtD
Trifluoperazine—Cough—Pamidronate—osteoporosis	0.00036	0.0024	CcSEcCtD
Trifluoperazine—Constipation—Calcitriol—osteoporosis	0.00036	0.0024	CcSEcCtD
Trifluoperazine—Convulsion—Pamidronate—osteoporosis	0.000358	0.00239	CcSEcCtD
Trifluoperazine—Urticaria—Estropipate—osteoporosis	0.000356	0.00238	CcSEcCtD
Trifluoperazine—Vision blurred—Zoledronate—osteoporosis	0.000356	0.00237	CcSEcCtD
Trifluoperazine—Body temperature increased—Estropipate—osteoporosis	0.000355	0.00237	CcSEcCtD
Trifluoperazine—Tremor—Zoledronate—osteoporosis	0.000353	0.00236	CcSEcCtD
Trifluoperazine—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000353	0.00236	CcSEcCtD
Trifluoperazine—Nervousness—Conjugated Estrogens—osteoporosis	0.000353	0.00235	CcSEcCtD
Trifluoperazine—Urticaria—Alendronate—osteoporosis	0.000351	0.00234	CcSEcCtD
Trifluoperazine—Body temperature increased—Alendronate—osteoporosis	0.000349	0.00233	CcSEcCtD
Trifluoperazine—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000349	0.00233	CcSEcCtD
Trifluoperazine—Agitation—Zoledronate—osteoporosis	0.000347	0.00231	CcSEcCtD
Trifluoperazine—Angioedema—Zoledronate—osteoporosis	0.000345	0.0023	CcSEcCtD
Trifluoperazine—Skin disorder—Risedronate—osteoporosis	0.000344	0.0023	CcSEcCtD
Trifluoperazine—Body temperature increased—Raloxifene—osteoporosis	0.000344	0.00229	CcSEcCtD
Trifluoperazine—Vision blurred—Conjugated Estrogens—osteoporosis	0.000342	0.00228	CcSEcCtD
Trifluoperazine—Urticaria—Ibandronate—osteoporosis	0.000342	0.00228	CcSEcCtD
Trifluoperazine—Body temperature increased—Ibandronate—osteoporosis	0.00034	0.00227	CcSEcCtD
Trifluoperazine—Leukopenia—Zoledronate—osteoporosis	0.000338	0.00225	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Pamidronate—osteoporosis	0.000337	0.00225	CcSEcCtD
Trifluoperazine—Urticaria—Calcitriol—osteoporosis	0.000335	0.00223	CcSEcCtD
Trifluoperazine—Body temperature increased—Calcitriol—osteoporosis	0.000333	0.00222	CcSEcCtD
Trifluoperazine—Angioedema—Conjugated Estrogens—osteoporosis	0.000332	0.00221	CcSEcCtD
Trifluoperazine—Hypersensitivity—Estropipate—osteoporosis	0.000331	0.00221	CcSEcCtD
Trifluoperazine—Cough—Zoledronate—osteoporosis	0.000329	0.0022	CcSEcCtD
Trifluoperazine—Oedema peripheral—Estradiol—osteoporosis	0.000329	0.00219	CcSEcCtD
Trifluoperazine—Rash—Etidronic acid—osteoporosis	0.000327	0.00218	CcSEcCtD
Trifluoperazine—Convulsion—Zoledronate—osteoporosis	0.000327	0.00218	CcSEcCtD
Trifluoperazine—Dermatitis—Etidronic acid—osteoporosis	0.000327	0.00218	CcSEcCtD
Trifluoperazine—Hypersensitivity—Alendronate—osteoporosis	0.000326	0.00217	CcSEcCtD
Trifluoperazine—Headache—Etidronic acid—osteoporosis	0.000325	0.00217	CcSEcCtD
Trifluoperazine—Asthenia—Estropipate—osteoporosis	0.000322	0.00215	CcSEcCtD
Trifluoperazine—Anorexia—Pamidronate—osteoporosis	0.000321	0.00214	CcSEcCtD
Trifluoperazine—Insomnia—Risedronate—osteoporosis	0.000321	0.00214	CcSEcCtD
Trifluoperazine—Pruritus—Estropipate—osteoporosis	0.000317	0.00212	CcSEcCtD
Trifluoperazine—Asthenia—Alendronate—osteoporosis	0.000317	0.00212	CcSEcCtD
Trifluoperazine—Hypersensitivity—Ibandronate—osteoporosis	0.000317	0.00211	CcSEcCtD
Trifluoperazine—Cough—Conjugated Estrogens—osteoporosis	0.000317	0.00211	CcSEcCtD
Trifluoperazine—Dyspnoea—Risedronate—osteoporosis	0.000316	0.00211	CcSEcCtD
Trifluoperazine—Hypotension—Pamidronate—osteoporosis	0.000315	0.0021	CcSEcCtD
Trifluoperazine—Convulsion—Conjugated Estrogens—osteoporosis	0.000315	0.0021	CcSEcCtD
Trifluoperazine—Dry mouth—Zoledronate—osteoporosis	0.000314	0.0021	CcSEcCtD
Trifluoperazine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000314	0.00209	CcSEcCtD
Trifluoperazine—Pruritus—Alendronate—osteoporosis	0.000313	0.00209	CcSEcCtD
Trifluoperazine—Constipation—Ethinyl Estradiol—osteoporosis	0.000311	0.00207	CcSEcCtD
Trifluoperazine—Hypersensitivity—Calcitriol—osteoporosis	0.00031	0.00207	CcSEcCtD
Trifluoperazine—Asthenia—Ibandronate—osteoporosis	0.000309	0.00206	CcSEcCtD
Trifluoperazine—Nausea—Etidronic acid—osteoporosis	0.000308	0.00206	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Zoledronate—osteoporosis	0.000308	0.00205	CcSEcCtD
Trifluoperazine—Fatigue—Risedronate—osteoporosis	0.000306	0.00204	CcSEcCtD
Trifluoperazine—Insomnia—Pamidronate—osteoporosis	0.000305	0.00203	CcSEcCtD
Trifluoperazine—Pruritus—Ibandronate—osteoporosis	0.000304	0.00203	CcSEcCtD
Trifluoperazine—Constipation—Risedronate—osteoporosis	0.000303	0.00202	CcSEcCtD
Trifluoperazine—Asthenia—Calcitriol—osteoporosis	0.000302	0.00202	CcSEcCtD
Trifluoperazine—Dyspnoea—Pamidronate—osteoporosis	0.0003	0.002	CcSEcCtD
Trifluoperazine—Somnolence—Pamidronate—osteoporosis	0.0003	0.002	CcSEcCtD
Trifluoperazine—Skin disorder—Zoledronate—osteoporosis	0.000299	0.002	CcSEcCtD
Trifluoperazine—Pruritus—Calcitriol—osteoporosis	0.000298	0.00199	CcSEcCtD
Trifluoperazine—Dizziness—Estropipate—osteoporosis	0.000297	0.00198	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000296	0.00198	CcSEcCtD
Trifluoperazine—Anorexia—Zoledronate—osteoporosis	0.000293	0.00196	CcSEcCtD
Trifluoperazine—Decreased appetite—Pamidronate—osteoporosis	0.000293	0.00195	CcSEcCtD
Trifluoperazine—Dizziness—Alendronate—osteoporosis	0.000292	0.00195	CcSEcCtD
Trifluoperazine—Erythema—Estradiol—osteoporosis	0.000291	0.00194	CcSEcCtD
Trifluoperazine—SIGMAR1—Levonorgestrel—Ethinyl Estradiol—osteoporosis	0.000291	0.0475	CbGdCrCtD
Trifluoperazine—Fatigue—Pamidronate—osteoporosis	0.000291	0.00194	CcSEcCtD
Trifluoperazine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000289	0.00193	CcSEcCtD
Trifluoperazine—Constipation—Pamidronate—osteoporosis	0.000288	0.00192	CcSEcCtD
Trifluoperazine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000288	0.00192	CcSEcCtD
Trifluoperazine—Hypotension—Zoledronate—osteoporosis	0.000288	0.00192	CcSEcCtD
Trifluoperazine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000287	0.00192	CcSEcCtD
Trifluoperazine—Dizziness—Raloxifene—osteoporosis	0.000287	0.00192	CcSEcCtD
Trifluoperazine—Dizziness—Ibandronate—osteoporosis	0.000284	0.0019	CcSEcCtD
Trifluoperazine—Rash—Estropipate—osteoporosis	0.000283	0.00189	CcSEcCtD
Trifluoperazine—Dermatitis—Estropipate—osteoporosis	0.000283	0.00189	CcSEcCtD
Trifluoperazine—Anorexia—Conjugated Estrogens—osteoporosis	0.000283	0.00189	CcSEcCtD
Trifluoperazine—Nervousness—Estradiol—osteoporosis	0.000282	0.00188	CcSEcCtD
Trifluoperazine—Urticaria—Risedronate—osteoporosis	0.000282	0.00188	CcSEcCtD
Trifluoperazine—Headache—Estropipate—osteoporosis	0.000281	0.00188	CcSEcCtD
Trifluoperazine—Body temperature increased—Risedronate—osteoporosis	0.00028	0.00187	CcSEcCtD
Trifluoperazine—Muscle spasms—Estradiol—osteoporosis	0.000279	0.00186	CcSEcCtD
Trifluoperazine—Rash—Alendronate—osteoporosis	0.000279	0.00186	CcSEcCtD
Trifluoperazine—Insomnia—Zoledronate—osteoporosis	0.000278	0.00186	CcSEcCtD
Trifluoperazine—Dermatitis—Alendronate—osteoporosis	0.000278	0.00186	CcSEcCtD
Trifluoperazine—Hypotension—Conjugated Estrogens—osteoporosis	0.000277	0.00185	CcSEcCtD
Trifluoperazine—Headache—Alendronate—osteoporosis	0.000277	0.00185	CcSEcCtD
Trifluoperazine—Dyspnoea—Zoledronate—osteoporosis	0.000274	0.00183	CcSEcCtD
Trifluoperazine—Rash—Raloxifene—osteoporosis	0.000274	0.00183	CcSEcCtD
Trifluoperazine—Dermatitis—Raloxifene—osteoporosis	0.000274	0.00183	CcSEcCtD
Trifluoperazine—Somnolence—Zoledronate—osteoporosis	0.000274	0.00183	CcSEcCtD
Trifluoperazine—Tremor—Estradiol—osteoporosis	0.000272	0.00182	CcSEcCtD
Trifluoperazine—Headache—Raloxifene—osteoporosis	0.000272	0.00182	CcSEcCtD
Trifluoperazine—Rash—Ibandronate—osteoporosis	0.000271	0.00181	CcSEcCtD
Trifluoperazine—Dermatitis—Ibandronate—osteoporosis	0.000271	0.00181	CcSEcCtD
Trifluoperazine—Headache—Ibandronate—osteoporosis	0.00027	0.0018	CcSEcCtD
Trifluoperazine—Insomnia—Conjugated Estrogens—osteoporosis	0.000268	0.00179	CcSEcCtD
Trifluoperazine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000268	0.00179	CcSEcCtD
Trifluoperazine—Decreased appetite—Zoledronate—osteoporosis	0.000268	0.00179	CcSEcCtD
Trifluoperazine—Agitation—Estradiol—osteoporosis	0.000267	0.00178	CcSEcCtD
Trifluoperazine—Nausea—Estropipate—osteoporosis	0.000266	0.00178	CcSEcCtD
Trifluoperazine—Body temperature increased—Pamidronate—osteoporosis	0.000266	0.00178	CcSEcCtD
Trifluoperazine—Angioedema—Estradiol—osteoporosis	0.000266	0.00177	CcSEcCtD
Trifluoperazine—Rash—Calcitriol—osteoporosis	0.000266	0.00177	CcSEcCtD
Trifluoperazine—Fatigue—Zoledronate—osteoporosis	0.000265	0.00177	CcSEcCtD
Trifluoperazine—Dermatitis—Calcitriol—osteoporosis	0.000265	0.00177	CcSEcCtD
Trifluoperazine—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000264	0.00176	CcSEcCtD
Trifluoperazine—Headache—Calcitriol—osteoporosis	0.000264	0.00176	CcSEcCtD
Trifluoperazine—Somnolence—Conjugated Estrogens—osteoporosis	0.000264	0.00176	CcSEcCtD
Trifluoperazine—Constipation—Zoledronate—osteoporosis	0.000263	0.00176	CcSEcCtD
Trifluoperazine—Nausea—Alendronate—osteoporosis	0.000262	0.00175	CcSEcCtD
Trifluoperazine—Hypersensitivity—Risedronate—osteoporosis	0.000261	0.00174	CcSEcCtD
Trifluoperazine—Asthenia—Ethinyl Estradiol—osteoporosis	0.000261	0.00174	CcSEcCtD
Trifluoperazine—Nausea—Raloxifene—osteoporosis	0.000258	0.00172	CcSEcCtD
Trifluoperazine—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000258	0.00172	CcSEcCtD
Trifluoperazine—Pruritus—Ethinyl Estradiol—osteoporosis	0.000257	0.00172	CcSEcCtD
Trifluoperazine—Fatigue—Conjugated Estrogens—osteoporosis	0.000256	0.00171	CcSEcCtD
Trifluoperazine—Nausea—Ibandronate—osteoporosis	0.000256	0.00171	CcSEcCtD
Trifluoperazine—Asthenia—Risedronate—osteoporosis	0.000254	0.0017	CcSEcCtD
Trifluoperazine—Cough—Estradiol—osteoporosis	0.000254	0.00169	CcSEcCtD
Trifluoperazine—Constipation—Conjugated Estrogens—osteoporosis	0.000253	0.00169	CcSEcCtD
Trifluoperazine—Pruritus—Risedronate—osteoporosis	0.000251	0.00167	CcSEcCtD
Trifluoperazine—Nausea—Calcitriol—osteoporosis	0.00025	0.00167	CcSEcCtD
Trifluoperazine—Hypersensitivity—Pamidronate—osteoporosis	0.000248	0.00166	CcSEcCtD
Trifluoperazine—Urticaria—Zoledronate—osteoporosis	0.000245	0.00163	CcSEcCtD
Trifluoperazine—Body temperature increased—Zoledronate—osteoporosis	0.000243	0.00162	CcSEcCtD
Trifluoperazine—Dry mouth—Estradiol—osteoporosis	0.000242	0.00161	CcSEcCtD
Trifluoperazine—Asthenia—Pamidronate—osteoporosis	0.000242	0.00161	CcSEcCtD
Trifluoperazine—Dizziness—Ethinyl Estradiol—osteoporosis	0.00024	0.0016	CcSEcCtD
Trifluoperazine—Pruritus—Pamidronate—osteoporosis	0.000238	0.00159	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Estradiol—osteoporosis	0.000237	0.00158	CcSEcCtD
Trifluoperazine—Urticaria—Conjugated Estrogens—osteoporosis	0.000235	0.00157	CcSEcCtD
Trifluoperazine—Dizziness—Risedronate—osteoporosis	0.000234	0.00156	CcSEcCtD
Trifluoperazine—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000234	0.00156	CcSEcCtD
Trifluoperazine—Skin disorder—Estradiol—osteoporosis	0.00023	0.00154	CcSEcCtD
Trifluoperazine—Rash—Ethinyl Estradiol—osteoporosis	0.000229	0.00153	CcSEcCtD
Trifluoperazine—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000229	0.00153	CcSEcCtD
Trifluoperazine—Headache—Ethinyl Estradiol—osteoporosis	0.000228	0.00152	CcSEcCtD
Trifluoperazine—Hypersensitivity—Zoledronate—osteoporosis	0.000227	0.00151	CcSEcCtD
Trifluoperazine—Rash—Risedronate—osteoporosis	0.000224	0.00149	CcSEcCtD
Trifluoperazine—Dermatitis—Risedronate—osteoporosis	0.000223	0.00149	CcSEcCtD
Trifluoperazine—Dizziness—Pamidronate—osteoporosis	0.000223	0.00149	CcSEcCtD
Trifluoperazine—Headache—Risedronate—osteoporosis	0.000222	0.00148	CcSEcCtD
Trifluoperazine—Asthenia—Zoledronate—osteoporosis	0.000221	0.00147	CcSEcCtD
Trifluoperazine—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000218	0.00146	CcSEcCtD
Trifluoperazine—Pruritus—Zoledronate—osteoporosis	0.000218	0.00145	CcSEcCtD
Trifluoperazine—Nausea—Ethinyl Estradiol—osteoporosis	0.000216	0.00144	CcSEcCtD
Trifluoperazine—Insomnia—Estradiol—osteoporosis	0.000215	0.00143	CcSEcCtD
Trifluoperazine—Asthenia—Conjugated Estrogens—osteoporosis	0.000213	0.00142	CcSEcCtD
Trifluoperazine—Rash—Pamidronate—osteoporosis	0.000213	0.00142	CcSEcCtD
Trifluoperazine—Dermatitis—Pamidronate—osteoporosis	0.000212	0.00142	CcSEcCtD
Trifluoperazine—Dyspnoea—Estradiol—osteoporosis	0.000212	0.00141	CcSEcCtD
Trifluoperazine—Headache—Pamidronate—osteoporosis	0.000211	0.00141	CcSEcCtD
Trifluoperazine—Somnolence—Estradiol—osteoporosis	0.000211	0.00141	CcSEcCtD
Trifluoperazine—Nausea—Risedronate—osteoporosis	0.000211	0.00141	CcSEcCtD
Trifluoperazine—Pruritus—Conjugated Estrogens—osteoporosis	0.00021	0.0014	CcSEcCtD
Trifluoperazine—Decreased appetite—Estradiol—osteoporosis	0.000206	0.00138	CcSEcCtD
Trifluoperazine—Fatigue—Estradiol—osteoporosis	0.000205	0.00136	CcSEcCtD
Trifluoperazine—Dizziness—Zoledronate—osteoporosis	0.000204	0.00136	CcSEcCtD
Trifluoperazine—Constipation—Estradiol—osteoporosis	0.000203	0.00135	CcSEcCtD
Trifluoperazine—Nausea—Pamidronate—osteoporosis	0.0002	0.00134	CcSEcCtD
Trifluoperazine—Dizziness—Conjugated Estrogens—osteoporosis	0.000196	0.00131	CcSEcCtD
Trifluoperazine—Rash—Zoledronate—osteoporosis	0.000194	0.0013	CcSEcCtD
Trifluoperazine—Dermatitis—Zoledronate—osteoporosis	0.000194	0.00129	CcSEcCtD
Trifluoperazine—Headache—Zoledronate—osteoporosis	0.000193	0.00129	CcSEcCtD
Trifluoperazine—Urticaria—Estradiol—osteoporosis	0.000188	0.00126	CcSEcCtD
Trifluoperazine—Body temperature increased—Estradiol—osteoporosis	0.000188	0.00125	CcSEcCtD
Trifluoperazine—Rash—Conjugated Estrogens—osteoporosis	0.000187	0.00125	CcSEcCtD
Trifluoperazine—Dermatitis—Conjugated Estrogens—osteoporosis	0.000187	0.00125	CcSEcCtD
Trifluoperazine—Headache—Conjugated Estrogens—osteoporosis	0.000186	0.00124	CcSEcCtD
Trifluoperazine—Nausea—Zoledronate—osteoporosis	0.000183	0.00122	CcSEcCtD
Trifluoperazine—Nausea—Conjugated Estrogens—osteoporosis	0.000176	0.00117	CcSEcCtD
Trifluoperazine—Hypersensitivity—Estradiol—osteoporosis	0.000175	0.00117	CcSEcCtD
Trifluoperazine—Asthenia—Estradiol—osteoporosis	0.00017	0.00114	CcSEcCtD
Trifluoperazine—Pruritus—Estradiol—osteoporosis	0.000168	0.00112	CcSEcCtD
Trifluoperazine—Dizziness—Estradiol—osteoporosis	0.000157	0.00105	CcSEcCtD
Trifluoperazine—Rash—Estradiol—osteoporosis	0.00015	0.000998	CcSEcCtD
Trifluoperazine—Dermatitis—Estradiol—osteoporosis	0.000149	0.000997	CcSEcCtD
Trifluoperazine—Headache—Estradiol—osteoporosis	0.000149	0.000992	CcSEcCtD
Trifluoperazine—Nausea—Estradiol—osteoporosis	0.000141	0.00094	CcSEcCtD
Trifluoperazine—CALM2—Immune System—AGER—osteoporosis	1.06e-05	6.39e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—AGER—osteoporosis	1.06e-05	6.39e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—POMC—osteoporosis	1.06e-05	6.38e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—POMC—osteoporosis	1.06e-05	6.37e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—ADCY5—osteoporosis	1.06e-05	6.36e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—ADCY5—osteoporosis	1.06e-05	6.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by NGF—IL6—osteoporosis	1.05e-05	6.33e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—IL6R—osteoporosis	1.05e-05	6.32e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—POMC—osteoporosis	1.04e-05	6.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—POMC—osteoporosis	1.04e-05	6.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—CYP19A1—osteoporosis	1.03e-05	6.23e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—IL6R—osteoporosis	1.03e-05	6.22e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—IL6R—osteoporosis	1.03e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PSMA5—osteoporosis	1.03e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PSMA2—osteoporosis	1.03e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PSMA2—osteoporosis	1.03e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PSMA5—osteoporosis	1.03e-05	6.21e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by NGF—IL6—osteoporosis	1.02e-05	6.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by NGF—IL6—osteoporosis	1.02e-05	6.12e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IRS1—osteoporosis	1.02e-05	6.12e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—IL6R—osteoporosis	1.01e-05	6.11e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—P4HB—osteoporosis	1.01e-05	6.1e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—IL6R—osteoporosis	1.01e-05	6.09e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—ADCY5—osteoporosis	1.01e-05	6.07e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—CYP19A1—osteoporosis	1e-05	6.02e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—CYP19A1—osteoporosis	1e-05	6.02e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GAPDH—osteoporosis	9.94e-06	5.98e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CALCA—osteoporosis	9.93e-06	5.98e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—ADCY5—osteoporosis	9.85e-06	5.93e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—ENO1—osteoporosis	9.8e-06	5.9e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—ADCY5—osteoporosis	9.8e-06	5.9e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—POMC—osteoporosis	9.79e-06	5.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—ADCY5—osteoporosis	9.76e-06	5.88e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—ADCY5—osteoporosis	9.76e-06	5.88e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—RAP1A—osteoporosis	9.68e-06	5.83e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PSMA2—osteoporosis	9.66e-06	5.82e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PSMA5—osteoporosis	9.66e-06	5.82e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CALCA—osteoporosis	9.61e-06	5.78e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CALCA—osteoporosis	9.61e-06	5.78e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IRS2—osteoporosis	9.56e-06	5.76e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IL6R—osteoporosis	9.55e-06	5.75e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—SPP1—osteoporosis	9.53e-06	5.74e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—SPP1—osteoporosis	9.48e-06	5.71e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IGF1—osteoporosis	9.41e-06	5.67e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MTHFR—osteoporosis	9.28e-06	5.59e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IRS2—osteoporosis	9.25e-06	5.57e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IRS2—osteoporosis	9.25e-06	5.57e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KL—osteoporosis	9.02e-06	5.43e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MTHFR—osteoporosis	8.97e-06	5.4e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MTHFR—osteoporosis	8.97e-06	5.4e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Hemostasis—TGFB1—osteoporosis	8.84e-06	5.32e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IRS2—osteoporosis	8.83e-06	5.31e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—POMC—osteoporosis	8.8e-06	5.3e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KL—osteoporosis	8.72e-06	5.25e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KL—osteoporosis	8.72e-06	5.25e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ADCY5—osteoporosis	8.65e-06	5.21e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IRS2—osteoporosis	8.62e-06	5.19e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—IL6R—osteoporosis	8.58e-06	5.17e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IRS2—osteoporosis	8.57e-06	5.16e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Hemostasis—TGFB1—osteoporosis	8.55e-06	5.15e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Hemostasis—TGFB1—osteoporosis	8.55e-06	5.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IRS2—osteoporosis	8.54e-06	5.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IRS2—osteoporosis	8.54e-06	5.14e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ADCY5—osteoporosis	8.51e-06	5.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—POMC—osteoporosis	8.51e-06	5.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—POMC—osteoporosis	8.51e-06	5.12e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ADCY5—osteoporosis	8.49e-06	5.11e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—ADCY5—osteoporosis	8.45e-06	5.09e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	8.44e-06	5.08e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—LEP—osteoporosis	8.43e-06	5.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—GPX1—osteoporosis	8.42e-06	5.07e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—LEP—osteoporosis	8.39e-06	5.05e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—SPP1—osteoporosis	8.37e-06	5.04e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ADCY5—osteoporosis	8.36e-06	5.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IRS1—osteoporosis	8.35e-06	5.02e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ADCY5—osteoporosis	8.33e-06	5.02e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—IL6R—osteoporosis	8.3e-06	5e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—IL6R—osteoporosis	8.3e-06	5e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—SPP1—osteoporosis	8.23e-06	4.96e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—SPP1—osteoporosis	8.21e-06	4.95e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—ADCY5—osteoporosis	8.17e-06	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—ADCY5—osteoporosis	8.17e-06	4.92e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—GPX1—osteoporosis	8.14e-06	4.9e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—GPX1—osteoporosis	8.14e-06	4.9e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—SPP1—osteoporosis	8.08e-06	4.87e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IRS1—osteoporosis	8.07e-06	4.86e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IRS1—osteoporosis	8.07e-06	4.86e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—SPP1—osteoporosis	8.06e-06	4.85e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—ESR1—osteoporosis	8.05e-06	4.85e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—ESR1—osteoporosis	8.01e-06	4.82e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL6R—osteoporosis	7.84e-06	4.72e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—CYP19A1—osteoporosis	7.84e-06	4.72e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ENO1—osteoporosis	7.82e-06	4.71e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—MTHFR—osteoporosis	7.77e-06	4.68e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PSMA5—osteoporosis	7.71e-06	4.64e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PSMA2—osteoporosis	7.71e-06	4.64e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IRS1—osteoporosis	7.7e-06	4.64e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL6R—osteoporosis	7.58e-06	4.57e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL6R—osteoporosis	7.58e-06	4.57e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IRS2—osteoporosis	7.57e-06	4.56e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IRS1—osteoporosis	7.52e-06	4.53e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—MTHFR—osteoporosis	7.52e-06	4.53e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—MTHFR—osteoporosis	7.52e-06	4.53e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IRS1—osteoporosis	7.48e-06	4.51e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IRS1—osteoporosis	7.45e-06	4.49e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IRS1—osteoporosis	7.45e-06	4.49e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IRS2—osteoporosis	7.45e-06	4.48e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IRS2—osteoporosis	7.43e-06	4.47e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—LEP—osteoporosis	7.4e-06	4.46e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IRS2—osteoporosis	7.31e-06	4.4e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IRS2—osteoporosis	7.29e-06	4.39e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—LEP—osteoporosis	7.29e-06	4.39e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—LEP—osteoporosis	7.27e-06	4.38e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—POMC—osteoporosis	7.25e-06	4.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IL6R—osteoporosis	7.24e-06	4.36e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—POMC—osteoporosis	7.21e-06	4.34e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling by GPCR—IL6—osteoporosis	7.2e-06	4.34e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—LEP—osteoporosis	7.15e-06	4.31e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—LEP—osteoporosis	7.13e-06	4.3e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—ESR1—osteoporosis	7.07e-06	4.26e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL6R—osteoporosis	7.07e-06	4.26e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ADCY5—osteoporosis	7.06e-06	4.25e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL6R—osteoporosis	7.03e-06	4.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IL6R—osteoporosis	7e-06	4.22e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IL6R—osteoporosis	7e-06	4.22e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IGF1—osteoporosis	6.97e-06	4.2e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—ESR1—osteoporosis	6.96e-06	4.19e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—ESR1—osteoporosis	6.94e-06	4.18e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IGF1—osteoporosis	6.93e-06	4.17e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—SPP1—osteoporosis	6.83e-06	4.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ADCY5—osteoporosis	6.83e-06	4.11e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ADCY5—osteoporosis	6.83e-06	4.11e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—ESR1—osteoporosis	6.83e-06	4.11e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—ESR1—osteoporosis	6.81e-06	4.1e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—SPP1—osteoporosis	6.61e-06	3.98e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—SPP1—osteoporosis	6.61e-06	3.98e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IRS1—osteoporosis	6.61e-06	3.98e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IRS1—osteoporosis	6.5e-06	3.91e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IRS1—osteoporosis	6.49e-06	3.91e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—ADCY5—osteoporosis	6.4e-06	3.85e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IRS1—osteoporosis	6.38e-06	3.84e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—GPX1—osteoporosis	6.38e-06	3.84e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IRS1—osteoporosis	6.36e-06	3.83e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—POMC—osteoporosis	6.36e-06	3.83e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—POMC—osteoporosis	6.26e-06	3.77e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—CYP19A1—osteoporosis	6.26e-06	3.77e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—POMC—osteoporosis	6.25e-06	3.76e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—POMC—osteoporosis	6.21e-06	3.74e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL6R—osteoporosis	6.21e-06	3.74e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IRS2—osteoporosis	6.18e-06	3.72e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—POMC—osteoporosis	6.15e-06	3.7e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—POMC—osteoporosis	6.13e-06	3.69e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IGF1—osteoporosis	6.12e-06	3.68e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL6R—osteoporosis	6.11e-06	3.68e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL6R—osteoporosis	6.09e-06	3.67e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—LEP—osteoporosis	6.05e-06	3.64e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IGF1—osteoporosis	6.02e-06	3.63e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—POMC—osteoporosis	6.01e-06	3.62e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—POMC—osteoporosis	6.01e-06	3.62e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IGF1—osteoporosis	6.01e-06	3.62e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Innate Immune System—IL6—osteoporosis	6e-06	3.61e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL6R—osteoporosis	5.99e-06	3.61e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IRS2—osteoporosis	5.98e-06	3.6e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IRS2—osteoporosis	5.98e-06	3.6e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL6R—osteoporosis	5.98e-06	3.6e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL1B—osteoporosis	5.96e-06	3.59e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IGF1—osteoporosis	5.91e-06	3.56e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IGF1—osteoporosis	5.9e-06	3.55e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—MTHFR—osteoporosis	5.89e-06	3.55e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—LEP—osteoporosis	5.85e-06	3.52e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—LEP—osteoporosis	5.85e-06	3.52e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Innate Immune System—IL6—osteoporosis	5.8e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Innate Immune System—IL6—osteoporosis	5.8e-06	3.49e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ESR1—osteoporosis	5.77e-06	3.48e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL1B—osteoporosis	5.77e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL1B—osteoporosis	5.77e-06	3.47e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—MYC—osteoporosis	5.66e-06	3.41e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—TGFB1—osteoporosis	5.64e-06	3.4e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ESR1—osteoporosis	5.59e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ESR1—osteoporosis	5.59e-06	3.36e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IRS1—osteoporosis	5.4e-06	3.25e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling by GPCR—IL6—osteoporosis	5.33e-06	3.21e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling by GPCR—IL6—osteoporosis	5.3e-06	3.19e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IRS1—osteoporosis	5.22e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IRS1—osteoporosis	5.22e-06	3.14e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—POMC—osteoporosis	5.2e-06	3.13e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ADCY5—osteoporosis	5.11e-06	3.08e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—GPX1—osteoporosis	5.09e-06	3.07e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL6R—osteoporosis	5.07e-06	3.05e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—POMC—osteoporosis	5.03e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—POMC—osteoporosis	5.03e-06	3.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IGF1—osteoporosis	5e-06	3.01e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL6R—osteoporosis	4.9e-06	2.95e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL6R—osteoporosis	4.9e-06	2.95e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IGF1—osteoporosis	4.83e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IGF1—osteoporosis	4.83e-06	2.91e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—POMC—osteoporosis	4.71e-06	2.84e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—MTHFR—osteoporosis	4.7e-06	2.83e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling by GPCR—IL6—osteoporosis	4.68e-06	2.82e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—IL6—osteoporosis	4.6e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—IL6—osteoporosis	4.59e-06	2.77e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—IL6—osteoporosis	4.52e-06	2.72e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—IL6—osteoporosis	4.51e-06	2.71e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MYC—osteoporosis	4.29e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—TGFB1—osteoporosis	4.28e-06	2.58e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IL6—osteoporosis	4.25e-06	2.56e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MYC—osteoporosis	4.19e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TGFB1—osteoporosis	4.18e-06	2.52e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MYC—osteoporosis	4.17e-06	2.51e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TGFB1—osteoporosis	4.16e-06	2.5e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MYC—osteoporosis	4.15e-06	2.5e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MYC—osteoporosis	4.15e-06	2.5e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—TGFB1—osteoporosis	4.14e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—TGFB1—osteoporosis	4.14e-06	2.49e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—IL6—osteoporosis	3.82e-06	2.3e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—POMC—osteoporosis	3.76e-06	2.26e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—IL6—osteoporosis	3.7e-06	2.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—IL6—osteoporosis	3.7e-06	2.23e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MYC—osteoporosis	3.68e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TGFB1—osteoporosis	3.67e-06	2.21e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MYC—osteoporosis	3.62e-06	2.18e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MYC—osteoporosis	3.61e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TGFB1—osteoporosis	3.61e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TGFB1—osteoporosis	3.6e-06	2.17e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MYC—osteoporosis	3.55e-06	2.14e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TGFB1—osteoporosis	3.54e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MYC—osteoporosis	3.54e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TGFB1—osteoporosis	3.53e-06	2.13e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL6—osteoporosis	3.49e-06	2.1e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL6—osteoporosis	3.38e-06	2.03e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL6—osteoporosis	3.38e-06	2.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IL6—osteoporosis	3.22e-06	1.94e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL6—osteoporosis	3.15e-06	1.9e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL6—osteoporosis	3.13e-06	1.89e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IL6—osteoporosis	3.12e-06	1.88e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IL6—osteoporosis	3.12e-06	1.88e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MYC—osteoporosis	3e-06	1.81e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TGFB1—osteoporosis	3e-06	1.8e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MYC—osteoporosis	2.91e-06	1.75e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MYC—osteoporosis	2.91e-06	1.75e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TGFB1—osteoporosis	2.9e-06	1.75e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TGFB1—osteoporosis	2.9e-06	1.75e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL6—osteoporosis	2.76e-06	1.66e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL6—osteoporosis	2.72e-06	1.64e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL6—osteoporosis	2.71e-06	1.63e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL6—osteoporosis	2.67e-06	1.61e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL6—osteoporosis	2.66e-06	1.6e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL6—osteoporosis	2.26e-06	1.36e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL6—osteoporosis	2.18e-06	1.32e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL6—osteoporosis	2.18e-06	1.32e-05	CbGpPWpGaD
